<DOC>
	<DOCNO>NCT02229539</DOCNO>
	<brief_summary>The purpose study test whether mouthwash make drug call doxepin reduce pain cause mouth sore result radiation therapy . A number mouth rinse preparation exist patient treatment-related oral mucositis pain DLA rinse , over-the-counter medication . This study evaluate effect doxepin compare DLA ( diphenhydramine , lidocaine antacid ) placebo.Doxepin approve Food Drug Administration ( FDA ) treatment depression , anxiety , long-term pain management , well management rash .</brief_summary>
	<brief_title>Doxepin Topical Rinse Treatment Acute Oral Mucositis Pain Patients Receiving Radiotherapy With Without Chemotherapy</brief_title>
	<detailed_description>Patients stratify accord sex ( male vs. female ) , concurrent use chemotherapy ( vs. yes ) , patient age registration ( &lt; 60 year old vs. ≥ 60 year old RTOG acute radiation morbidity criterion ( 1 vs. 2 v 3 ) . Protocol therapy consist 2 cycle . Patients randomize one three treatment regimen , include doxepin , DLA placebo . Cycle One consist one day . The care provider nurse confirm oral pain least 4 10 severity level time rinse first day study . Patient ask complete baseline evaluation Oral Symptoms booklet . If pain score le 4 administration delay pain least 4 . Cycle Two consist optional continuation phase last 7 day . Initiation Cycle 2/Continuation Phase may delay one week Cycle 1/Day 1 . Primary Objective : 1 . Determine whether doxepin rinse DLA rinse effective placebo reduce OM-related pain patient undergo RT oral cavity , measure patient-reported questionnaire baseline , 5 minute , 15 minute , 30 minute , 1 hour , 2 hour , 4 hour . Secondary Objectives : 1 . Assess adverse event profile doxepin rinse , DLA rinse agent , placebo use patient-reported questionnaire 5 minute , 15 minute , 30 minute , 1 hour , 2 hour , 4 hour domains unpleasant taste , burn sting discomfort , drowsiness . 2 . Compare incidence use additional analgesic 1 4 hour initial mouthwash , doxepin oral rinse , DLA rinse agent , placebo arm . 3 . Compare length time study product use patient one-week continuation phase . 4 . Compare daily pain score one-week continuation phase three study arm . 5 . Compare 24-hour morphine equivalent dose use continuation phase three study arm .</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Doxepin</mesh_term>
	<mesh_term>Antacids</mesh_term>
	<mesh_term>Anti-Ulcer Agents</mesh_term>
	<criteria>1 . Documentation Disease : Histologic documentation malignancy currently undergo course RT ( without chemotherapy ) include oral cavity and/or oropharyngeal area dose least 4500 cGy use 5 fraction ( i.e. , stereotactic body radiation therapy [ SBRT ] allow ) . 2 . Physical exam demonstrate evidence radiotherapyrelated mucositis visible oral cavity and/or oropharynx consistent mucous membrane toxicity great 0 use Acute Radiation Morbidity Scoring Criteria . 3 . At least 4 ( 10 ) patientreported oral pain related oral mucositis secondary RT patient seek relief , measure Oral Pain Assessment . Note : The pain score must least 4 time patient start first dose study medication . The patient may enrol study s/he , time , pain score least 4 , long initiation study treatment begin pain score least 4 . 4 . Ability complete questionnaire ( ) assistance . 5 . No known allergy diphenhydramine , lidocaine , antacid ( aluminum hydroxide , magnesium hydroxide , simethicone ) , doxepin , tricyclic antidepressant , know component drug formulation test arm . 6 . No use antiarrhythmic medication ( except betablockers ) include lidocaine , linezolid , ipratropium , medication high anticholinergic potency ( include neostigmine , tricyclic antidepressant monoamine oxidase inhibitor ) within 2 week prior registration . 7 . No current diagnose untreated unresolved oral candidiasis oral HSV infection . 8 . No history untreated narrow angle glaucoma within 6 week prior registration . 9 . No untreated urinary retention within 6 week prior registration . 10 . No current use glutamine sucralfate powder time registration ( washout require ) . 11 . No cryotherapy prophylactic mucosal protection within 6 week prior registration . 12 . Not pregnant , patient eligible study receive radiotherapy , know genotoxic , mutagenic teratogenic effect . Therefore , woman childbearing potential , negative pregnancy test do ≤ 28 day prior registration require . 13 . Age ≥ 18 year 14 . ECOG Performance Status 0 , 1 , 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>